Second pilot rapid assessment on ‘Renal denervation systems for treatment-resistant hypertension’
The purpose of the assessment is to assess the effectiveness and safety of renal denervation systems for patients who suffer from treatment-resistant hypertension compared to standard of care (no treatment, additional pharmacological treatment, device-based hypertension therapy and sham treatment). Final version of the assessment was published in December 2013 Below is the documentation provided by […]
Final Project Plan on the second pilot rapid assessment on “Renal denervation systems for treatment-resistant hypertension”
Find the final project plan attached at the bottom of this page. Find the full second pilot assessment here. You can also find the summary document of comments and authors’ replies of the review of the 2nd draft version of the pilot assessment here. WP5 Strand B_2nd pilot_Project Plan
EUnetHTA-EMA f-t-f meeting summary 20130514, London UK
Please find below the summary of the EUnetHTA / EMA face-to-face meeting, 14 May, 2013, London, UK EUnetHTA-EMA f-t-f meeting summary 20130514 London UK
EUnetHTA-EFPIA Framework for Collaboration
EUnetHTA and EFPIA are pleased to announce that they have agreed to closely collaborate to facilitate the involvement of pharmaceutical companies in the pilot work in Joint Action 2. A joint advisory working group will discuss how to facilitate continuous process improvements, so that the pilots can best address the viability and usefulness and the […]
EUnetHTA’s joint response to the public consultation on PAES_comments from HAS
PAES comments_HAS final
EUnetHTA’s joint response to the public consultation on PAES
EUnetHTA’s joint response to the public consultation on PAES
National report based on pilot assessment of a vaccine using the HTA Core Model® published
LBI, (Ludwig Boltzmann Institute for Health Technology Assessment) Austria, has published a national report based on a EUnetHTA pilot rapid assessment of the herpes zoster vaccine, Zostavax®. Since 2006, a vaccine against Herpes Zoster (Zostavax®) has been licensed for people over 50 years of age. A systematic pilot rapid relative effectiveness assessment of the vaccine […]
EUnetHTA Joint Position to EMA Public consultation on draft policy on the publication and access to clinical trial data
This document is the completed consultation form submitted 30 September, 2013 as the EUnetHTA Joint Position response to the public consultation on the EMA draft policy on the publication and access to clinical trial data. EUnetHTA Consultation Forum_final_20130919.pdf
WP7 SG1 Concept paper on Osteoarthritis
This document is WP7’s concept paper on osteoarthritis titled the “EunetHTA guideline on data requirements for the assessment of health technologies used for the treatment of osteoarthritis of the hip and knee”. EUnetHTA disease-specific guidelines aim to give recommendations about type of data to be produced during the development of technologies (initial evidence generation) to support […]
HTA Core Model Terms of Use Version 1.1
This new version of the terms of use contains key principles relevant to HTA Core Model users. Version 1.1 replaces the first version produced in 2008. The new version contains two licenses, one for non-commercial use and another for commercial use. It is the first ToU to allow also commercial use. As of July 2013, […]
